clinical trial · NCT05039099
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
AL-S Pharma·phase2·completed·n = 73
Amyotrophic Lateral SclerosisAP-101Placebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
started
Sep 2, 2021
primary completion
Aug 13, 2025
completion
Aug 13, 2025
last updated
Aug 19, 2025
official title
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacodynamic Markers, and Pharmacokinetics of AP-101 in Patients With Familial Amyotrophic Lateral Sclerosis (fALS) and Sporadic Amyotrophic Lateral Sclerosis (sALS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol